Clinical trial results for
esophageal or gastroesophageal junction
cancer after surgery
Esophageal or gastroesophageal junction
(GEJ) cancer that has been treated with
chemoradiation followed by surgery to help
prevent it from coming back
Actor portrayals.
An FDA-approved immunotherapy that helped people live longer without their cancer returning compared to placebo
About the clinical trial
In a clinical trial of 794 people who had received chemoradiation followed by surgery to remove their esophageal or GEJ cancer, 532 people were given OPDIVO and 262 people were given placebo.
People given OPDIVO lived longer without their cancer returning compared to placebo
OPDIVO
Half the people remained free of their cancer returning
Placebo
Half the people remained free of their cancer returning
People given OPDIVO after chemoradiation and surgery had a 31% lower risk of their esophageal or GEJ cancer returning compared to people given placebo.
OPDIVO will not work for everyone. Individual results may vary.
OPDIVO Qvantig may be a faster* way to receive treatment.
It is not known if OPDIVO Qvantig is safe and effective in children. OPDIVO Qvantig cannot be used in combination with ipilimumab.
*A 3-5 minute injection time of OPDIVO Qvantig compared to a 30-minute infusion time of OPDIVO. This does not account for all aspects of treatment. Does not include observation time. Actual clinic time may vary.
Getting treatment
See treatment plans and what to expect from an intravenous (IV) infusion or under-the-skin injection (subcutaneous injection)
For adults with esophageal or gastroesophageal junction (GEJ) cancer who have been treated with chemoradiation followed by surgery to help prevent it from coming back
As an intravenous infusion
OPDIVO® (nivolumab) is a prescription medicine that may be used in adults to help prevent cancer of the tube that connects your throat to your stomach (esophageal cancer) or cancer where the esophagus joins the stomach (gastroesophageal junction cancer) from coming back after it has been treated with chemoradiation followed by surgery to completely remove the cancer, but some cancer cells were still present in the removed tumor or lymph nodes.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
As a subcutaneous injection
OPDIVO Qvantig™ (nivolumab + hyaluronidase-nvhy) is a prescription medicine used alone in adults to help prevent cancer of the tube that connects your throat to your stomach (esophageal cancer) or cancer where the esophagus joins the stomach (gastroesophageal junction cancer) from coming back after it has been treated with chemoradiation followed by surgery to completely remove the cancer, but some cancer cells were still present in the removed tumor or lymph nodes.
It is not known if OPDIVO Qvantig is safe and effective in children.